Jim Cramer Says “Let ImmunityBio Be Your Speculation” to a Caller

ImmunityBio, Inc. (NASDAQ:IBRX) was among the stocks on which Jim Cramer commented, as he emphasized that SpaceX investors are betting on Elon Musk rather than the company’s earnings. When a caller mentioned that, as per their observation, the company seems to have become a “mid-cap commercial revenue generator” from a “small-cap spec play,” Cramer remarked:

I think that’s a good way to look at it. But I will tell you that’s going to be your spec. Remember, in How to Make Money in Any Market, I encourage speculation as long as it’s only one position. If you own two positions, then I don’t encourage it. Let ImmunityBio be your speculation.

Photo by Artem Podrez on Pexels

ImmunityBio, Inc. (NASDAQ:IBRX) develops therapies designed to strengthen the immune system against infectious diseases and several cancers. A caller inquired about the stock during the April 17 episode, and Cramer commented:

You know there’s a lot of dispute about what they did. And I’m going to tell you that it is not clear exactly what they did wrong, but they got in trouble… I got to see how they get out of trouble, and then we’ll take a hard look at it.

While we acknowledge the risk and potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IBRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1